Lantheus Holdings logo

Lantheus HoldingsNASDAQ: LNTH

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 June 2015

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$6.01 B
-30%vs. 3y high
90%vs. sector
-94%vs. 3y high
19%vs. sector
-66%vs. 3y high
83%vs. sector
-56%vs. 3y high
56%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:58:27 GMT
$86.40$0.00(0.00%)

Dividend

No data over the past 3 years
$378.73 M$375.86 M
$378.73 M$131.09 M

Analysts recommendations

Institutional Ownership

LNTH Latest News

Why Lantheus Holdings Stock Won Big on Wednesday
fool.com20 November 2024 Sentiment: POSITIVE

Why Lantheus Holdings Stock Won Big on Wednesday

Lantheus Announces Share Repurchase Program
globenewswire.com20 November 2024 Sentiment: POSITIVE

BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months.

Lantheus to Present at the Jefferies London Healthcare Conference
globenewswire.com13 November 2024 Sentiment: POSITIVE

BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20.

Lantheus Holdings: Q3 Results Were Good But Market Overreacted
seekingalpha.com08 November 2024 Sentiment: POSITIVE

Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnostic imaging for prostate cancer and heart conditions, respectively, with significant market potential and government support. Despite a conservative Q4 outlook, Lantheus' forward P/E of 13 and projected 15% annual revenue growth present an attractive buying opportunity.

Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript
seekingalpha.com06 November 2024 Sentiment: NEUTRAL

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Matt Taylor - Jefferies Larry Solow - CJS Securities Tara Bancroft - TD Cowen Yuan Zhi - B. Riley Kemp Dolliver - Brookline Capital Markets Justin Walsh - Jones Trading Andy Hsieh - William Blair Ed Ridley-Day - Redburn Atlantic Operator Good morning.

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
globenewswire.com04 November 2024 Sentiment: POSITIVE

BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services' (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule, announced and detailed on the CMS website late Friday, recognizes the value of and ensures broad patient access to specialized diagnostic radiopharmaceuticals by improving the accuracy of payment amounts for these products.

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
globenewswire.com23 October 2024 Sentiment: POSITIVE

BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024.

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
globenewswire.com15 September 2024 Sentiment: POSITIVE

Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was

Lantheus Appoints Julie Eastland as New Board Member
globenewswire.com05 September 2024 Sentiment: POSITIVE

BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
globenewswire.com28 August 2024 Sentiment: POSITIVE

BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4.

What type of business is Lantheus Holdings?

Lantheus Holdings, Inc. is one of the world leaders in the development, manufacturing, and commercialization of innovative agents and products for medical imaging, which help doctors in the diagnosis and treatment of cardiovascular and other diseases. Clinicians use the company's agents and products in a variety of imaging methods, including echocardiography and nuclear imaging. The company was founded in 1956, with its headquarters located in Billerica, Massachusetts, USA. The company's current portfolio consists of ten commercial products. The current products include contrast agents for ultrasound and medical radiopharmaceuticals for nuclear imaging.

What sector is Lantheus Holdings in?

Lantheus Holdings is in the Healthcare sector

What industry is Lantheus Holdings in?

Lantheus Holdings is in the Drug Manufacturers - Specialty & Generic industry

What country is Lantheus Holdings from?

Lantheus Holdings is headquartered in United States

When did Lantheus Holdings go public?

Lantheus Holdings initial public offering (IPO) was on 25 June 2015

What is Lantheus Holdings website?

https://www.lantheus.com

Is Lantheus Holdings in the S&P 500?

No, Lantheus Holdings is not included in the S&P 500 index

Is Lantheus Holdings in the NASDAQ 100?

No, Lantheus Holdings is not included in the NASDAQ 100 index

Is Lantheus Holdings in the Dow Jones?

No, Lantheus Holdings is not included in the Dow Jones index

When was Lantheus Holdings the previous earnings report?

No data

When does Lantheus Holdings earnings report?

The next expected earnings date for Lantheus Holdings is 21 February 2025